Autosomal Recessive Progressive External Ophthalmoplegia 1: Disease-Characteristics Report

Executive summary and evidence scope

Autosomal recessive progressive external ophthalmoplegia 1 (arPEO1) is a nuclear-encoded mitochondrial DNA-maintenance disorder caused by biallelic germline variants in POLG, which encodes the catalytic subunit of mitochondrial DNA polymerase γ. The defining manifestation is slowly progressive, usually bilateral ptosis and external ophthalmoparesis; limb, bulbar, peripheral-nerve, cerebellar, auditory, epileptic, or other systemic features produce a “PEO-plus” phenotype. POLG dysfunction causes secondary mitochondrial-DNA (mtDNA) deletions and sometimes depletion, followed by respiratory-chain failure in energy-demanding tissues. The entity is one phenotype on a continuous POLG-related disease spectrum rather than a sharply isolated syndrome. (wong2008molecularandclinical pages 1-2, kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 6-8)

Evidence specific to molecularly confirmed arPEO1 is sparse. Accordingly, this report distinguishes arPEO-specific evidence, broader POLG-spectrum evidence, and genetically heterogeneous PEO evidence. The most recent disease-focused source retrieved was the January 2024 CPEO review (DOI 10.3390/brainsci14020135); it is authoritative for current recognition and management but not arPEO1-specific. No arPEO1-specific randomized trial, population natural-history registry, or 2023–2024 mechanistic cohort was identified. (ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5, rahman2019polgrelateddisordersand pages 11-13)

The following table provides a knowledge-base-ready overview.

Table: This table condenses the key knowledge-base fields for autosomal recessive progressive external ophthalmoplegia 1 as supported by the gathered POLG-related evidence. It highlights what is well supported, what is broader-spectrum rather than arPEO1-specific, and which ontology identifiers still require external verification.

1. Disease information

Definition and classification

arPEO1 is a Mendelian, autosomal-recessive mitochondrial disease in which impaired POLG-dependent mtDNA replication and maintenance predominantly injure extraocular and skeletal muscle. It is distinct from:

• autosomal-dominant PEO caused by dominant POLG variants;
• PEO caused by other nuclear genes, including TWNK, POLG2, RNASEH1, SLC25A4, TK2, and RRM2B;
• primary mtDNA point variants or single large-scale mtDNA deletions; and
• syndromic PEO such as Kearns–Sayre syndrome. (ali2024mitochondrialchronicprogressive pages 6-8, kierdaszuk2020progressiveexternalophthalmoplegia pages 2-4, rodriguezlopez2020clinicalpathologicaland pages 2-3)

Identifiers and synonyms

• OMIM: 258450, explicitly identified as POLG-associated arPEO in the retrieved primary literature. (wong2008molecularandclinical pages 1-2)
• MONDO: not verified in the retrieved corpus; manual ontology reconciliation is recommended because databases may represent PEO as a phenotype-level, gene-specific, or umbrella mitochondrial-disease concept.
• Common names: autosomal recessive progressive external ophthalmoplegia 1; PEOA1; arPEO; POLG-related autosomal recessive PEO; POLG-related PEO; chronic progressive external ophthalmoplegia when chronicity is emphasized.
• ICD-10/ICD-11 and MeSH: no uniquely specific arPEO1 code was verified; coding commonly falls under mitochondrial metabolism/myopathy or ophthalmoplegia categories. A generic code should not be represented as disease-specific without local terminology verification.

This report is synthesized from aggregated disease-level literature, published cohorts, individual case reports, biochemical experiments, and model systems, not from an individual EHR.

2. Etiology, risk, protective factors, and gene–environment interaction

Primary cause

The cause is two pathogenic or likely pathogenic POLG alleles in trans. POLG encodes POLγA, the catalytic polymerase/proofreading component of the mitochondrial replisome. Recessive variants reduce polymerase activity, processivity, DNA binding, interaction with the POLG2 accessory subunit, or protein abundance, destabilizing mtDNA. In one approximately 350-patient referral series, two mutant alleles were found in 31 unrelated recessive cases, of whom 4/31 (13%) had arPEO; this is a referral-series proportion, not population prevalence. (wong2008molecularandclinical pages 1-2)

Genetic risk factors

Recurrent disease alleles across the broader POLG spectrum include p.Ala467Thr (A467T), p.Trp748Ser (W748S), p.Gly848Ser (G848S), and the p.Thr251Ile–p.Pro587Leu cis pair. A467T represented approximately 36% of disease-associated POLG alleles in a major review; these four recurrent alleles together constituted about 50% of identified variants, and roughly 75% of patients carried at least one. These values concern all POLG-related disease, not arPEO1 alone. (rahman2019polgrelateddisordersand pages 10-11)

A467T carrier frequency was reported as approximately 0.2–0.3% in mixed European populations and 1.3–1.4% in Belgian/British populations, with a theoretical homozygote frequency of approximately 1:500,000–1:1,000,000. This is allele epidemiology, not clinical arPEO1 prevalence, because homozygous A467T can cause widely differing POLG phenotypes. (rajakulendran2016aclinicalneuropathological pages 2-3, rajakulendran2016aclinicalneuropathological pages 11-13)

Modifiers and protective factors

• E1143G, usually found in cis with W748S, partially compensates for biochemical impairment and may modify severity; it should not be treated as a stand-alone protective allele. (somai2025mitochondrialdnareplication pages 6-8, rahman2019polgrelateddisordersand pages 10-11)
• Homozygous A467T has produced Alpers–Huttenlocher syndrome, MELAS-like disease, MEMSA, and SANDO, implicating mtDNA haplotype, other nuclear variants, and environmental stress as modifiers. No validated clinical modifier panel exists. (rajakulendran2016aclinicalneuropathological pages 2-3, rajakulendran2016aclinicalneuropathological pages 11-13)
• No reproducible genetic or environmental protective factor specific to arPEO1 was identified.

Environmental and lifestyle factors

No toxin, infection, diet, occupation, smoking pattern, alcohol exposure, or radiation exposure causes this Mendelian disorder. Physiological stress may unmask mitochondrial insufficiency, but arPEO1-specific gene–environment effect sizes are unavailable. The most consequential established drug interaction in the broader POLG spectrum is valproate-associated hepatic failure; valproate is therefore contraindicated in patients with pathogenic POLG variants. (rahman2019polgrelateddisordersand pages 11-13)

3. Phenotypes

Core and associated manifestations

(kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5, rodriguezlopez2020clinicalpathologicaland pages 2-3)

Onset, progression, frequency, and quality of life

The classic arPEO phenotype is generally adult-onset, chronic, and slowly progressive, although POLG disease spans infancy through late adulthood. Reliable phenotype percentages for arPEO1 alone are unavailable. A heterogeneous mitochondrial PEO cohort of 89 patients comprised 42% pure PEO, 10% Kearns–Sayre syndrome, 33% myopathic PEO-plus, 12% bulbar PEO-plus, and 3% other PEO-plus; these figures should not be imported as arPEO1 frequencies. In that cohort, POLG was more often associated with PEO-plus than pure PEO. (rodriguezlopez2020clinicalpathologicaland pages 2-3)

Quality-of-life effects include impaired superior and peripheral visual fields from ptosis, abnormal head posture, difficulty reading/driving, fatigue, reduced walking endurance, falls from neuropathy/ataxia, dysphagia, and psychosocial burden. No arPEO1-specific EQ-5D, SF-36, PROMIS, or utility study was identified.

4. Genetic and molecular information

Gene and protein

• Gene: POLG, chromosome 15q region; HGNC identifier should be verified directly before database import.
• Protein: catalytic subunit POLγA; it contains exonuclease, spacer, and polymerase domains and works with a POLG2-encoded accessory dimer.
• Origin: pathogenic variants are constitutional/germline, not somatic drivers.

Variant classes and functional consequences

Reported pathogenic classes include missense, nonsense, frameshift, canonical/noncanonical splice, and small insertion/deletion variants. A 2021 adult PEO case carried compound-heterozygous c.67_88del, p.Gly23Serfs*236 and c.3104+3A>T; the latter causes exon-19 skipping. Muscle showed mitochondrial myopathy, multiple mtDNA deletions, and depletion. (kurtz2021wholeexomesequencingidentifies pages 7-7)

A467T lies in the spacer domain. Recombinant enzyme retained only about 4% of wild-type polymerase activity, had impaired DNA binding/processivity, and failed to interact normally with the POLG2 accessory subunit. W748S reduces polymerase activity, processivity, and DNA binding while retaining accessory-subunit interaction. These are primarily loss-of-function/hypomorphic mechanisms in recessive disease, not classic gain-of-function or dominant-negative effects. (rahman2019polgrelateddisordersand pages 10-11, rajakulendran2016aclinicalneuropathological pages 11-13, stuart2006mitochondrialandnuclear pages 8-9)

Population allele frequencies must be assessed variant by variant in gnomAD; the retrieved corpus did not provide validated gnomAD frequencies for every pathogenic allele. ClinVar classifications should likewise be imported per exact HGVS allele rather than assigning one classification to all variants.

Other genomic and epigenetic findings

No recurrent chromosomal aneuploidy, translocation, inversion, repeat expansion, or disease-defining copy-number abnormality is established. No validated arPEO1-specific methylation episignature, histone signature, or chromatin defect was identified. A reported mtDNA-deletion case involving reduced POLG/SSBP1 expression and methylation is not sufficient to define an arPEO1 epigenetic mechanism.

5. Environmental information

Environmental exposures are not primary etiologic agents. There is no evidence that infection is causal or transmissible; zoonotic transmission is not applicable. Practical exposure management follows general mitochondrial-disease principles: avoid fasting, dehydration, excessive heat, and unaccustomed exhaustive exertion when these provoke decompensation, while maintaining safe activity. These are precautionary practices rather than proven arPEO1-preventive interventions. Valproate avoidance has the strongest POLG-specific evidence. (rahman2019polgrelateddisordersand pages 11-13)

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic trigger: biallelic POLG dysfunction.
2. Primary biochemical defect: reduced polymerase catalysis/processivity, DNA binding, proofreading in selected alleles, holoenzyme assembly, or protein abundance.
3. Genome-maintenance failure: replication fork stalling, mtDNA depletion and/or clonally expanded multiple mtDNA deletions in post-mitotic tissues.
4. Respiratory defect: loss or imbalance of mtDNA-encoded oxidative-phosphorylation subunits impairs electron transport and ATP production.
5. Cellular injury: energy failure, abnormal redox state, compensatory mitochondrial proliferation, and eventual myofiber/neuronal dysfunction or loss.
6. Clinical expression: extraocular-muscle weakness causes ptosis and ophthalmoplegia; broader skeletal-muscle and neural injury causes PEO-plus manifestations. (wong2008molecularandclinical pages 1-2, kurtz2021wholeexomesequencingidentifies pages 7-7, somai2025mitochondrialdnareplication pages 6-8, chan2009dnapolymerasegamma pages 4-5)

Extraocular muscles are especially vulnerable because of continuous activity, specialized motor units, and high oxidative demand. Adult-onset PEO has been associated with multiple deletions affecting more than 60% of muscle mtDNA genomes in reviewed data, although this is not a universal diagnostic threshold. (somai2025mitochondrialdnareplication pages 6-8)

Ontology suggestions

• GO biological process: mitochondrial DNA replication; mitochondrial genome maintenance; DNA repair; oxidative phosphorylation; ATP metabolic process; mitochondrial organization.
• GO molecular function: DNA-directed DNA polymerase activity; 3′–5′ exonuclease activity; DNA binding.
• GO cellular component: mitochondrion; mitochondrial matrix; mitochondrial nucleoid; mitochondrial respiratory-chain complex.
• Cell Ontology: skeletal muscle fiber/myocyte; extraocular skeletal muscle cell where supported; peripheral sensory neuron; cerebellar neuron.

Exact ontology accessions other than HP:0000508 were not verified in the retrieved literature and should undergo ontology-service validation.

Molecular profiling and advanced technologies

Routine diagnosis measures mtDNA quantity/rearrangement and respiratory histochemistry rather than a validated transcriptomic, proteomic, metabolomic, or lipidomic signature. No arPEO1-specific single-cell atlas, spatial-transcriptomic map, integrated multi-omics classifier, or CRISPR-screen-derived clinical biomarker was identified. The absence of retrieved evidence should be encoded as “not established,” not “normal.”

7. Anatomical structures affected

• Primary organ/tissue: bilateral extraocular muscles and levator palpebrae superioris; skeletal muscle.
• Secondary systems in PEO-plus disease: peripheral and central nervous systems, auditory system, swallowing musculature, liver, heart, endocrine and renal systems—variable and not obligatory in isolated arPEO1. (ali2024mitochondrialchronicprogressive pages 6-8)
• Subcellular site: mitochondrial matrix/nucleoid and downstream inner-membrane respiratory-chain system.
• Lateralization: typically bilateral, often relatively symmetric; asymmetric ptosis can occur clinically.

Suggested anatomy annotations include extraocular muscle, levator palpebrae superioris, skeletal muscle tissue, peripheral nerve, cerebellum, brain, liver, and heart. UBERON/FMA accessions should be verified before import.

8. Temporal development

Onset is usually insidious and adult, beginning with subtle saccadic slowing, ptosis, or gaze limitation. Early disease may remain ocular; intermediate disease can add diplopia, exercise intolerance, and limb weakness; advanced PEO-plus disease can include bulbar dysfunction, neuropathy, ataxia, hearing loss, or other organ involvement. The course is chronic and usually slowly progressive rather than episodic or relapsing. Spontaneous remission is not expected, although ptosis and diplopia can improve symptomatically after intervention. (kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 3-5)

There is no accepted staging system or validated arPEO1 progression-rate biomarker. Early molecular diagnosis is the main actionable window because it enables surveillance, avoids harmful treatment, and informs relatives before irreversible disability accumulates.

9. Inheritance and population

Inheritance is autosomal recessive. Parents of an affected individual are usually heterozygous carriers; each full sibling has a theoretical 25% probability of being affected, 50% of being an unaffected carrier, and 25% of inheriting neither familial allele, assuming both variants are confirmed in trans and standard Mendelian segregation applies.

Penetrance is likely high for genuinely pathogenic biallelic combinations but is age- and allele-dependent; expressivity is markedly variable. Anticipation is not established. Germline mosaicism has not emerged as a characteristic mechanism. Consanguinity increases the probability of homozygous rare alleles but is not required. Founder enrichment exists for selected alleles such as A467T in European-derived populations. No consistent sex bias is established. (rajakulendran2016aclinicalneuropathological pages 2-3, rahman2019polgrelateddisordersand pages 10-11)

Neither incidence nor prevalence of clinically defined arPEO1 is robustly known. Carrier-frequency estimates for A467T must not be converted directly into disease prevalence because penetrance, allelic heterogeneity, and phenotype heterogeneity intervene.

10. Diagnostics

Recommended workflow

1. Clinical recognition: bilateral progressive ptosis plus external ophthalmoparesis, slowed saccades, exercise intolerance, neuropathy, ataxia, or family history.
2. Exclude common mimics: ocular myasthenia gravis, thyroid eye disease, oculopharyngeal muscular dystrophy, myotonic dystrophy, congenital cranial dysinnervation disorders, inflammatory/infiltrative orbital disease, and other mitochondrial PEO causes.
3. First-line molecular testing: a mitochondrial-disease/PEO nuclear panel that includes POLG plus complete mtDNA sequencing and deletion analysis, or exome/genome sequencing with reliable mtDNA and copy-number/rearrangement analysis. Definitive arPEO1 diagnosis requires two disease-causing POLG alleles in trans. WES identified the novel frameshift in the 2021 adult case. (kurtz2021wholeexomesequencingidentifies pages 7-7)
4. Tissue-aware mtDNA testing: blood can miss low-level or tissue-restricted deletions; skeletal muscle is often more informative for multiple mtDNA deletions and depletion.
5. Muscle biopsy when genetics is unresolved or tissue mtDNA analysis is required: modified Gomori trichrome, COX/SDH histochemistry, respiratory-chain studies, mtDNA copy number, and deletion testing.

In a heterogeneous 89-person PEO cohort, muscle biopsy showed mitochondrial dysfunction in 95%, and a genetic diagnosis was reached in 96%; 63% had a single large mtDNA deletion, 26% multiple deletions, and 7% an mtDNA point variant. Among multiple-deletion cases, causal genes included TWNK (n=8), POLG (n=7), TK2 (n=6), and RRM2B (n=2). These data demonstrate diagnostic yield but are not arPEO1 prevalence estimates. (rodriguezlopez2020clinicalpathologicaland pages 2-3)

CK has limited sensitivity: in the same broader cohort, 31/68 had CK below 200 U/L; elevated results averaged 780 U/L and ranged from 203–5,195 U/L. Normal CK therefore does not exclude disease. FGF21 and GDF15 may support a mitochondrial diagnosis, but neither is specific for POLG arPEO1. (rodriguezlopez2020clinicalpathologicaland pages 2-3)

EMG may show myopathy or neuropathy; nerve-conduction testing is useful when sensory ataxia is present. ECG/echocardiography, audiology, swallowing assessment, pulmonary testing, EEG, and brain MRI should be driven by phenotype. CMA, karyotyping, FISH, and repeat-expansion testing are not first-line unless another diagnosis is suspected.

Screening

Population and newborn screening are not established. Appropriate strategies are cascade testing for known familial variants, partner testing where relevant, and surveillance of genetically affected relatives. Carrier screening is targeted rather than universal.

11. Outcome and prognosis

Isolated adult arPEO is generally chronic and disabling but not necessarily life-shortening. Prognosis becomes less favorable with seizures, encephalopathy, severe neuropathy/ataxia, dysphagia, respiratory weakness, cardiomyopathy, or hepatic involvement. Published survival rates, median life expectancy, disease-specific mortality rates, and validated prognostic models for arPEO1 were not identified.

The major durable morbidity is ocular and neuromuscular disability. Recovery of lost mitochondrial myofibers is not expected; supportive interventions improve function rather than cure the molecular defect. Variant alone is an imperfect prognostic marker: even homozygous A467T produced four markedly different clinical phenotypes in a four-patient study. (rajakulendran2016aclinicalneuropathological pages 2-3, rajakulendran2016aclinicalneuropathological pages 11-13)

12. Treatment and current implementation

Disease-modifying therapy

No approved disease-modifying pharmacotherapy, gene therapy, cell therapy, RNA therapy, or gene-editing treatment exists for arPEO1. An authoritative review stated that evidence-based POLG therapies were lacking and no randomized controlled trials had been performed. Vitamin/antioxidant “mitochondrial cocktails” are widely used but lack a proven arPEO1 response rate. (rahman2019polgrelateddisordersand pages 11-13)

Symptomatic and supportive care

• Ptosis: eyelid crutches may be tried but are often poorly tolerated. Mild levator dysfunction may be treated by levator resection/advancement; severe dysfunction often requires frontalis/brow suspension. Corneal exposure risk must be balanced against visual-field benefit. Suggested NCIt concepts: Ptosis Repair; Frontalis Suspension Procedure; Supportive Care. (ali2024mitochondrialchronicprogressive pages 3-5, rahman2019polgrelateddisordersand pages 11-13)
• Diplopia/strabismus: prisms when feasible; selected patients may undergo strabismus surgery, with counseling that progression can alter alignment. Suggested NCIt: Prism Therapy; Strabismus Surgery. (ali2024mitochondrialchronicprogressive pages 3-5)
• Rehabilitation: individualized aerobic and resistance activity below symptom-provoking thresholds, physical/occupational therapy, falls prevention, and mobility aids. Suggested NCIt: Physical Therapy; Occupational Therapy; Rehabilitation Therapy.
• Bulbar/respiratory care: swallowing evaluation, diet modification, speech therapy, aspiration prevention, nutritional support, and noninvasive ventilation where indicated.
• Hearing/cataract care: hearing aids or cochlear assessment and cataract surgery when clinically appropriate. Cataract removal and brow suspension are specifically cited supportive interventions in POLG disease. (rahman2019polgrelateddisordersand pages 11-13)
• Seizures: specialist management; lamotrigine, clobazam, levetiracetam, or topiramate have been used, but comparative arPEO1 data are absent. Valproate is absolutely contraindicated because of potentially fatal hepatic failure. (rahman2019polgrelateddisordersand pages 11-13)
• Monitoring: periodic ophthalmology, neurology, mobility/falls, hearing, swallowing, nutrition, respiratory, cardiac, hepatic, endocrine, and mental-health assessment, tailored to phenotype.

No arPEO1-specific interventional trial was identified in the retrieved ClinicalTrials.gov search. Trials of elamipretide and other interventions enrolled broader primary mitochondrial myopathy or nuclear-DNA mitochondrial-disease populations; they should not be presented as demonstrated arPEO1 treatments.

13. Prevention

Primary prevention by lifestyle change is impossible once a pathogenic biallelic genotype is inherited. Evidence-based prevention is reproductive and familial:

• genetic counseling and confirmation that variants are in trans;
• parental and cascade testing;
• prenatal diagnosis or preimplantation genetic testing for a known familial genotype;
• donor gametes or other reproductive options according to patient values and jurisdiction.

Mitochondrial replacement therapy is not a logical targeted prevention for POLG arPEO1 because the causal variants are in nuclear DNA, not maternally inherited mtDNA. Secondary prevention comprises early molecular diagnosis and surveillance. Tertiary prevention includes valproate avoidance, falls/aspiration prevention, corneal protection, safe rehabilitation, and management of cardiac, respiratory, hepatic, auditory, and nutritional complications. Vaccination has no disease-specific preventive role beyond routine infection prevention.

14. Other species and natural disease

POLG is evolutionarily conserved, with functional orthologues in mammals, Drosophila, and yeast (MIP1 in Saccharomyces cerevisiae, NCBI Taxonomy 4932). No well-established naturally occurring companion-animal or wildlife syndrome equivalent to human POLG arPEO1, no breed-specific VBO association, and no zoonotic potential were identified. Comparative relevance therefore comes primarily from engineered models rather than natural veterinary disease.

15. Model organisms and experimental systems

Yeast

Human PEO-associated substitutions introduced into yeast MIP1 reproduce mtDNA loss, respiratory-deficient “petite” colonies, altered mutability, and variant-specific dominance/recessivity. The yeast I416T analogue of human A467T was mild in haploids and nearly wild-type in diploids, consistent with recessive inheritance. Yeast models predict pathogenicity with reported accuracy of approximately 70–100%, but are limited by nonconserved residues, simplified protein interactions, and absence of extraocular muscle and nervous-system phenotypes. (stuart2006mitochondrialandnuclear pages 1-2, stuart2006mitochondrialandnuclear pages 8-9, lodi2015dnapolymeraseγ pages 7-8, lodi2015dnapolymeraseγ pages 8-9)

A concise abstract-level statement from the yeast literature is that MIP1 models help in “validating the pathological mutations found in human POLG” and in defining their molecular defects. Chemical rescue with lipoic acid or MitoQ reduced petite frequency for selected yeast variants, but this is preclinical and not evidence of efficacy in arPEO1 patients. (lodi2015dnapolymeraseγ pages 9-10)

Biochemical and patient-cell systems

Recombinant POLγ assays measure polymerase activity, processivity, DNA binding, proofreading, and POLG2 interaction. Patient fibroblasts have demonstrated nonsense-mediated decay, abnormal splicing, and reduced holoenzyme abundance; examples included approximately 75% reduction with R232H/G848S and 45% reduction with A467T/T914P combinations. These systems directly test variant function but do not reproduce lifelong tissue-selective deletion accumulation. (chan2009dnapolymerasegamma pages 4-5, lodi2015dnapolymeraseγ pages 9-10)

Mouse models

Exonuclease-deficient POLG “mutator” mice develop premature aging at 6–9 months, including hearing loss, kyphosis, cardiomegaly, reduced body weight and bone density, and approximately 90-fold more mtDNA deletions. Heterozygotes can remain asymptomatic despite markedly elevated mutation burden, demonstrating that mutagenesis alone does not determine phenotype. These models illuminate deletion-driven mitochondrial pathology but do not faithfully reproduce human arPEO1. (somai2025mitochondrialdnareplication pages 6-8, rahman2019polgrelateddisordersand pages 8-10)

Key research gaps and current expert interpretation

The most important unresolved issue is why identical biallelic POLG genotypes produce isolated adult PEO in some people and catastrophic multisystem disease in others. Current evidence supports contributions from residual enzyme activity, allelic phase, mtDNA background, nuclear modifiers, tissue-specific deletion thresholds, aging, and environmental stress, but no validated predictive model exists. (rajakulendran2016aclinicalneuropathological pages 2-3, rahman2019polgrelateddisordersand pages 10-11, rajakulendran2016aclinicalneuropathological pages 11-13)

Recent clinical practice has moved toward broad sequencing and tissue-aware mtDNA analysis rather than sequential single-gene testing, while the therapeutic field remains supportive. Priorities are longitudinal genotype-stratified natural-history cohorts, quantitative ocular-motility endpoints, patient-derived myotube/iPSC models, single-cell and spatial profiling of affected muscle, and safe nuclear-gene replacement or editing strategies. The central current conclusion is therefore: molecular diagnosis is clinically actionable for counseling, surveillance, and drug avoidance, but not yet for a proven genotype-directed cure.

Selected dated sources and URLs

1. Wong et al. “Molecular and clinical genetics of mitochondrial diseases due to POLG mutations.” Human Mutation. September 2008. DOI: 10.1002/humu.20824. Primary human referral series. (wong2008molecularandclinical pages 1-2)
2. Rahman & Copeland. “POLG-related disorders and their neurological manifestations.” Nature Reviews Neurology. Online November 2018/2019 volume. DOI: 10.1038/s41582-018-0101-0. Authoritative review. (rahman2019polgrelateddisordersand pages 10-11, rahman2019polgrelateddisordersand pages 11-13)
3. Rodríguez-López et al. “Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia.” Journal of Medical Genetics. March 2020; 57:643–646. DOI: 10.1136/jmedgenet-2019-106649. Primary clinical cohort. (rodriguezlopez2020clinicalpathologicaland pages 2-3)
4. Kurtz et al. “Whole-Exome Sequencing Identifies a Novel POLG Frameshift Variant…” Case Reports in Genetics. November 2021. DOI: 10.1155/2021/9969071. Primary human case and molecular study. (kurtz2021wholeexomesequencingidentifies pages 7-7)
5. Ali, Esmaeil & Behbehani. “Mitochondrial Chronic Progressive External Ophthalmoplegia.” Brain Sciences. January 2024;14:135. DOI: 10.3390/brainsci14020135. Recent clinical review. Its abstract states: “Genetic sequencing is the gold standard for diagnosing mitochondrial encephalomyopathies” and “No definitive treatment option is available for mitochondrial diseases.” (ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5)

PMIDs were not consistently exposed in the retrieved full-text metadata; DOI URLs are therefore supplied rather than risking incorrect PMID assignment.

References

1. (wong2008molecularandclinical pages 1-2): Lee-Jun C. Wong, Robert K. Naviaux, Nicola Brunetti-Pierri, Qing Zhang, Eric S. Schmitt, Cavatina Truong, Margherita Milone, Bruce H. Cohen, Beverly Wical, Jaya Ganesh, Alice A. Basinger, Barbara K. Burton, Kathryn Swoboda, Donald L. Gilbert, Adeline Vanderver, Russell P. Saneto, Bruno Maranda, Georgianne Arnold, Jose E. Abdenur, Paula J. Waters, and William C. Copeland. Molecular and clinical genetics of mitochondrial diseases due to polg mutations. Human Mutation, 29:E150-E172, Sep 2008. URL: https://doi.org/10.1002/humu.20824, doi:10.1002/humu.20824. This article has 366 citations and is from a domain leading peer-reviewed journal.

2. (kurtz2021wholeexomesequencingidentifies pages 7-7): Justin Kurtz, Joseph Americo Fernandes, Mahesh Mansukhani, William C. Copeland, and Ali B. Naini. Whole-exome sequencing identifies a novel polg frameshift variant in an adult patient presenting with progressive external ophthalmoplegia and mitochondrial dna depletion. Case Reports in Genetics, 2021:1-7, Nov 2021. URL: https://doi.org/10.1155/2021/9969071, doi:10.1155/2021/9969071. This article has 4 citations.

3. (ali2024mitochondrialchronicprogressive pages 6-8): Ali Ali, Ali Esmaeil, and Raed Behbehani. Mitochondrial chronic progressive external ophthalmoplegia. Brain Sciences, 14:135, Jan 2024. URL: https://doi.org/10.3390/brainsci14020135, doi:10.3390/brainsci14020135. This article has 25 citations.

4. (ali2024mitochondrialchronicprogressive pages 3-5): Ali Ali, Ali Esmaeil, and Raed Behbehani. Mitochondrial chronic progressive external ophthalmoplegia. Brain Sciences, 14:135, Jan 2024. URL: https://doi.org/10.3390/brainsci14020135, doi:10.3390/brainsci14020135. This article has 25 citations.

5. (rahman2019polgrelateddisordersand pages 11-13): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 508 citations and is from a highest quality peer-reviewed journal.

6. (somai2025mitochondrialdnareplication pages 6-8): Shruti Somai, Chioma H. Aloh, Dillon E. King, and William C. Copeland. Mitochondrial dna replication and disease: a historical perspective on molecular insights and therapeutic advances. International Journal of Molecular Sciences, 26:10275, Oct 2025. URL: https://doi.org/10.3390/ijms262110275, doi:10.3390/ijms262110275. This article has 1 citations.

7. (rodriguezlopez2020clinicalpathologicaland pages 2-3): Claudia Rodríguez-López, Luis M. García-Cárdaba, Alberto Blázquez, Pablo Serrano-Lorenzo, Gerardo Gutiérrez-Gutiérrez, Beatriz San Millán-Tejado, Nuria Muelas, Aurelio Hernández-Laín, Juan J. Vílchez, Eduardo Gutiérrez-Rivas, Joaquín Arenas, Miguel A. Martín, and Cristina Domínguez-González. Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia. Journal of Medical Genetics, 57(9):643-646, Mar 2020. URL: https://doi.org/10.1136/jmedgenet-2019-106649, doi:10.1136/jmedgenet-2019-106649. This article has 43 citations and is from a domain leading peer-reviewed journal.

8. (rahman2019polgrelateddisordersand pages 10-11): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 508 citations and is from a highest quality peer-reviewed journal.

9. (chan2009dnapolymerasegamma pages 4-5): Sherine S.L. Chan and William C. Copeland. Dna polymerase gamma and mitochondrial disease: understanding the consequence of polg mutations. Biochimica et biophysica acta, 1787 5:312-9, May 2009. URL: https://doi.org/10.1016/j.bbabio.2008.10.007, doi:10.1016/j.bbabio.2008.10.007. This article has 249 citations.

10. (rajakulendran2016aclinicalneuropathological pages 2-3): Sanjeev Rajakulendran, Robert D. S. Pitceathly, Jan-Willem Taanman, Harry Costello, Mary G. Sweeney, Cathy E. Woodward, Zane Jaunmuktane, Janice L. Holton, Thomas S. Jacques, Brian N. Harding, Carl Fratter, Michael G. Hanna, and Shamima Rahman. A clinical, neuropathological and genetic study of homozygous a467t polg-related mitochondrial disease. PLoS ONE, 11:e0145500, Jan 2016. URL: https://doi.org/10.1371/journal.pone.0145500, doi:10.1371/journal.pone.0145500. This article has 67 citations and is from a peer-reviewed journal.

11. (stuart2006mitochondrialandnuclear pages 8-9): Gregory R. Stuart, Janine H. Santos, Micheline K. Strand, Bennett Van Houten, and William C. Copeland. Mitochondrial and nuclear dna defects in saccharomyces cerevisiae with mutations in dna polymerase γ associated with progressive external ophthalmoplegia. Human Molecular Genetics, 15:363-374, Jan 2006. URL: https://doi.org/10.1093/hmg/ddi454, doi:10.1093/hmg/ddi454. This article has 74 citations and is from a domain leading peer-reviewed journal.

12. (rajakulendran2016aclinicalneuropathological pages 11-13): Sanjeev Rajakulendran, Robert D. S. Pitceathly, Jan-Willem Taanman, Harry Costello, Mary G. Sweeney, Cathy E. Woodward, Zane Jaunmuktane, Janice L. Holton, Thomas S. Jacques, Brian N. Harding, Carl Fratter, Michael G. Hanna, and Shamima Rahman. A clinical, neuropathological and genetic study of homozygous a467t polg-related mitochondrial disease. PLoS ONE, 11:e0145500, Jan 2016. URL: https://doi.org/10.1371/journal.pone.0145500, doi:10.1371/journal.pone.0145500. This article has 67 citations and is from a peer-reviewed journal.

13. (kierdaszuk2020progressiveexternalophthalmoplegia pages 2-4): Biruta Kierdaszuk, Magdalena Kaliszewska, Joanna Rusecka, Joanna Kosińska, Ewa Bartnik, Katarzyna Tońska, Anna M. Kamińska, and Anna Kostera-Pruszczyk. Progressive external ophthalmoplegia in polish patients—from clinical evaluation to genetic confirmation. Genes, 12:54, Dec 2020. URL: https://doi.org/10.3390/genes12010054, doi:10.3390/genes12010054. This article has 6 citations.

14. (stuart2006mitochondrialandnuclear pages 1-2): Gregory R. Stuart, Janine H. Santos, Micheline K. Strand, Bennett Van Houten, and William C. Copeland. Mitochondrial and nuclear dna defects in saccharomyces cerevisiae with mutations in dna polymerase γ associated with progressive external ophthalmoplegia. Human Molecular Genetics, 15:363-374, Jan 2006. URL: https://doi.org/10.1093/hmg/ddi454, doi:10.1093/hmg/ddi454. This article has 74 citations and is from a domain leading peer-reviewed journal.

15. (rahman2019polgrelateddisordersand pages 8-10): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 508 citations and is from a highest quality peer-reviewed journal.

16. (lodi2015dnapolymeraseγ pages 7-8): Tiziana Lodi, Cristina Dallabona, Cecilia Nolli, Paola Goffrini, Claudia Donnini, and Enrico Baruffini. Dna polymerase γ and disease: what we have learned from yeast. Frontiers in Genetics, Mar 2015. URL: https://doi.org/10.3389/fgene.2015.00106, doi:10.3389/fgene.2015.00106. This article has 41 citations and is from a peer-reviewed journal.

17. (lodi2015dnapolymeraseγ pages 8-9): Tiziana Lodi, Cristina Dallabona, Cecilia Nolli, Paola Goffrini, Claudia Donnini, and Enrico Baruffini. Dna polymerase γ and disease: what we have learned from yeast. Frontiers in Genetics, Mar 2015. URL: https://doi.org/10.3389/fgene.2015.00106, doi:10.3389/fgene.2015.00106. This article has 41 citations and is from a peer-reviewed journal.

18. (lodi2015dnapolymeraseγ pages 9-10): Tiziana Lodi, Cristina Dallabona, Cecilia Nolli, Paola Goffrini, Claudia Donnini, and Enrico Baruffini. Dna polymerase γ and disease: what we have learned from yeast. Frontiers in Genetics, Mar 2015. URL: https://doi.org/10.3389/fgene.2015.00106, doi:10.3389/fgene.2015.00106. This article has 41 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00